Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.

Abstract:

:Triple-negative breast cancer (TNBC), the most refractory subtype of breast cancer to current treatments, accounts disproportionately for the majority of breast cancer-related deaths. This is largely due to cancer plasticity and the development of cancer stem cells (CSCs). Recently, distinct yet interconvertible mesenchymal-like and epithelial-like states have been revealed in breast CSCs. Thus, strategies capable of simultaneously inhibiting bulk and CSC populations in both mesenchymal and epithelial states have yet to be developed. Wnt/β-catenin and Hippo/YAP pathways are crucial in tumorigenesis, but importantly also possess tumor suppressor functions in certain contexts. One possibility is that TNBC cells in epithelial or mesenchymal state may differently affect Wnt/β-catenin and Hippo/YAP signaling and CSC phenotypes. In this report, we found that YAP signaling and CD44high /CD24-/low CSCs were upregulated while Wnt/β-catenin signaling and ALDH+ CSCs were downregulated in mesenchymal-like TNBC cells, and vice versa in their epithelial-like counterparts. Dual knockdown of YAP and Wnt/β-catenin, but neither alone, was required for effective suppression of both CD44high /CD24-/low and ALDH+ CSC populations in mesenchymal and epithelial TNBC cells. These observations were confirmed with cultured tumor fragments prepared from patients with TNBC after treatment with Wnt inhibitor ICG-001 and YAP inhibitor simvastatin. In addition, a clinical database showed that decreased gene expression of Wnt and YAP was positively correlated with decreased ALDH and CD44 expression in patients' samples while increased patient survival. Furthermore, tumor growth of TNBC cells in either epithelial or mesenchymal state was retarded, and both CD44high /CD24-/low and ALDH+ CSC subpopulations were diminished in a human xenograft model after dual administration of ICG-001 and simvastatin. Tumorigenicity was also hampered after secondary transplantation. These data suggest a new therapeutic strategy for TNBC via dual Wnt and YAP inhibition.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Sulaiman A,McGarry S,Li L,Jia D,Ooi S,Addison C,Dimitroulakos J,Arnaout A,Nessim C,Yao Z,Ji G,Song H,Gadde S,Li X,Wang L

doi

10.1002/1878-0261.12167

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

423-440

issue

4

eissn

1574-7891

issn

1878-0261

journal_volume

12

pub_type

杂志文章
  • Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

    abstract::Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast ca...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.07.005

    authors: Gasch C,Oldopp T,Mauermann O,Gorges TM,Andreas A,Coith C,Müller V,Fehm T,Janni W,Pantel K,Riethdorf S

    更新日期:2016-10-01 00:00:00

  • Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines.

    abstract::The PI3K/Akt signaling pathway, the most frequently altered signaling system in human cancer, is a crucial inducer of dysregulated proliferation and neoplastic processes; however, few therapeutic strategies using PI3K/Akt inhibitors singly have been shown to be effective. The purpose of this paper was to underline the...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12888

    authors: Fabi F,Adam P,Parent S,Tardif L,Cadrin M,Asselin E

    更新日期:2020-12-18 00:00:00

  • Near infrared photoimmunotherapy of B-cell lymphoma.

    abstract::Near infrared photoimmunotherapy (NIR-PIT) is a new, highly-selective cancer theranostics that employs an antibody-photo absorber conjugate (APC). NIR-PIT has successfully treated preclinical tumor models with APCs and is now in the first-in-human phase 1 clinical trial for head and neck cancer patients against EGFR. ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.07.010

    authors: Nagaya T,Nakamura Y,Sato K,Harada T,Choyke PL,Kobayashi H

    更新日期:2016-11-01 00:00:00

  • Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

    abstract:PURPOSE:DNA analysis by NGS has become important to direct the clinical care of cancer patients. However, NGS is not successful in all cases, and the factors responsible for test failures have not been systematically evaluated. MATERIALS AND METHODS:A series of 1528 solid and hematolymphoid tumor specimens was tested ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.05.004

    authors: Al-Kateb H,Nguyen TT,Steger-May K,Pfeifer JD

    更新日期:2015-11-01 00:00:00

  • The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

    abstract:BACKGROUND:Breast cancer is a heterogeneous disease with different molecular subtypes that have varying responses to therapy. An ongoing challenge in breast cancer research is to distinguish high-risk patients from good prognosis patients. This is particularly difficult in the low-grade, ER-positive luminal A tumors, w...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.11.002

    authors: Montes de Oca R,Gurard-Levin ZA,Berger F,Rehman H,Martel E,Corpet A,de Koning L,Vassias I,Wilson LO,Meseure D,Reyal F,Savignoni A,Asselain B,Sastre-Garau X,Almouzni G

    更新日期:2015-03-01 00:00:00

  • Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

    abstract::CDC25 (cell division cycle 25) phosphatases are essential for cell cycle control under normal conditions and in response to DNA damage. They are represented by three isoforms, CDC25A, B and C, each of them being submitted to an alternative splicing mechanism. Alternative splicing of many genes is affected in response ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2012.06.003

    authors: Albert H,Battaglia E,Monteiro C,Bagrel D

    更新日期:2012-10-01 00:00:00

  • Targeting breast cancer stem cells.

    abstract::The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of the tumor. Although, the CSC hypothesis does not directly address the cell of origin of cancer, it is...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2010.06.005

    authors: McDermott SP,Wicha MS

    更新日期:2010-10-01 00:00:00

  • A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial-mesenchymal transition.

    abstract::As a critical feature of the tumor microenvironment, hypoxia is known to be a potent inducer of tumor metastasis, and it has been proposed that the initial steps in metastasis involve epithelial-mesenchymal transition (EMT). The strong correlation among hypoxia, EMT, and metastasis suggests that integrative assessment...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12491

    authors: Chen YL,Zhang Y,Wang J,Chen N,Fang W,Zhong J,Liu Y,Qin R,Yu X,Sun Z,Gao F

    更新日期:2019-07-01 00:00:00

  • Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice.

    abstract::Targeted toxin-based therapeutics are hindered by poor intracellular uptake, limited stability and non-specific immune stimulation. To address these problems, ligand-targeted toxins in combination with low dose saponin mixtures have been adapted and tested in vivo in the past, however, undefined saponin raw mixtures a...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2012.12.004

    authors: Thakur M,Mergel K,Weng A,von Mallinckrodt B,Gilabert-Oriol R,Dürkop H,Melzig MF,Fuchs H

    更新日期:2013-06-01 00:00:00

  • Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

    abstract::The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.03.004

    authors: Cignetto S,Modica C,Chiriaco C,Fontani L,Milla P,Michieli P,Comoglio PM,Vigna E

    更新日期:2016-06-01 00:00:00

  • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

    abstract::Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more real-time representation of a tumor and its molecular heterogeneity than tissue. Howe...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12791

    authors: Charo LM,Eskander RN,Okamura R,Patel SP,Nikanjam M,Lanman RB,Piccioni DE,Kato S,McHale MT,Kurzrock R

    更新日期:2021-01-01 00:00:00

  • Stromal SPOCK1 supports invasive pancreatic cancer growth.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is marked by an abundant stromal deposition. This stroma is suspected to harbor both tumor-promoting and tumor-suppressing properties. This is underscored by the disappointing results of stroma targeting in clinical studies. Given the complexity of tumor-stroma interaction in PD...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12073

    authors: Veenstra VL,Damhofer H,Waasdorp C,Steins A,Kocher HM,Medema JP,van Laarhoven HW,Bijlsma MF

    更新日期:2017-08-01 00:00:00

  • DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.

    abstract::Short arm of chromosome 8 is a hot spot for chromosomal breaks, losses and amplifications in breast cancer. Although such genetic changes may have phenotypic consequences, the identity of candidate gene(s) remains to be clearly defined. Pol β gene is localized to chromosome 8p12-p11 and encodes a key DNA base excision...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.01.001

    authors: Abdel-Fatah TM,Russell R,Agarwal D,Moseley P,Abayomi MA,Perry C,Albarakati N,Ball G,Chan S,Caldas C,Ellis IO,Madhusudan S

    更新日期:2014-05-01 00:00:00

  • Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

    abstract::Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evalu...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.09.010

    authors: Kamieniak MM,Rico D,Milne RL,Muñoz-Repeto I,Ibáñez K,Grillo MA,Domingo S,Borrego S,Cazorla A,García-Bueno JM,Hernando S,García-Donas J,Hernández-Agudo E,Y Cajal TR,Robles-Díaz L,Márquez-Rodas I,Cusidó M,Sáez R,Lacambr

    更新日期:2015-02-01 00:00:00

  • Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.

    abstract::Hydrophobic neoantigens are more immunogenic because they are better presented by the major histocompatibility complex and better recognized by T cells. Tumor cells can evade the immune response by expressing checkpoints such as programmed death ligand 1. Checkpoint blockade reactivates immune recognition and can be e...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12748

    authors: Pham TV,Boichard A,Goodman A,Riviere P,Yeerna H,Tamayo P,Kurzrock R

    更新日期:2020-08-01 00:00:00

  • Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.

    abstract::Glioblastoma (GBM) is an incurable brain tumor for which new treatment strategies are urgently needed. Next-generation sequencing of GBM has most often been performed retrospectively and on archival tissue from both diagnostic and relapse surgeries with limited knowledge of clinical information, including treatment gi...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12790

    authors: Nørøxe DS,Yde CW,Østrup O,Michaelsen SR,Schmidt AY,Kinalis S,Torp MH,Skjøth-Rasmussen J,Brennum J,Hamerlik P,Poulsen HS,Nielsen FC,Lassen U

    更新日期:2020-09-04 00:00:00

  • Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis.

    abstract::Breast cancer (BrCa) metabolism is geared toward biomass synthesis and maintenance of reductive capacity. Changes in glucose and glutamine metabolism in BrCa have been widely reported, yet the contribution of fatty acids (FAs) in BrCa biology remains to be determined. We recently reported that adipocyte coculture alte...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12368

    authors: Balaban S,Lee LS,Varney B,Aishah A,Gao Q,Shearer RF,Saunders DN,Grewal T,Hoy AJ

    更新日期:2018-09-01 00:00:00

  • Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

    abstract::The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient (inter-patient heterogeneity), and within an individual (intra-patient heterogeneity) as demon...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2014.09.011

    authors: Catenacci DV

    更新日期:2015-05-01 00:00:00

  • Adipose tissue from metabolic syndrome mice induces an aberrant miRNA signature highly relevant in prostate cancer development.

    abstract::Prostate cancer (PCa) remains an important public health concern in Western countries. Metabolic syndrome (MeS) is a cluster of pathophysiological disorders with increasing prevalence in the general population that is a risk factor for PCa. Several studies have determined that a crosstalk between white adipose tissue ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12788

    authors: Massillo C,Duca RB,Lacunza E,Dalton GN,Farré PL,Taha N,Piccioni F,Scalise GD,Gardner K,De Siervi A

    更新日期:2020-09-02 00:00:00

  • Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.

    abstract::Deregulation of the insulin-like growth factor (IGF) axis and dysbalance of components of the IGF system as potential therapeutic targets have been described in different tumor types. IGF2 is a major embryonic growth factor and an important activator of IGF signaling. It is regulated by imprinting in a development- an...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12164

    authors: Küffer S,Gutting T,Belharazem D,Sauer C,Michel MS,Marx A,Trojan L,Ströbel P

    更新日期:2018-02-01 00:00:00

  • Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.

    abstract::Breast cancer is a heterogeneous disease that can be divided in subtypes based on histology, gene expression profiles as well as differences in genomic aberrations. Distinct global DNA methylation profiles have been reported in normal breast epithelial cells as well as in breast tumors. However, the influence of the t...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2010.11.004

    authors: Rønneberg JA,Fleischer T,Solvang HK,Nordgard SH,Edvardsen H,Potapenko I,Nebdal D,Daviaud C,Gut I,Bukholm I,Naume B,Børresen-Dale AL,Tost J,Kristensen V

    更新日期:2011-02-01 00:00:00

  • APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

    abstract::Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12138

    authors: Shah F,Goossens E,Atallah NM,Grimard M,Kelley MR,Fishel ML

    更新日期:2017-12-01 00:00:00

  • miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.

    abstract::Deregulation of microRNAs contributes to the aberrant growth of hepatocellular carcinoma (HCC). Here, we showed that miR-634 expression was frequently decreased in HCC. Low miR-634 expression was significantly associated with larger tumor size, poorer tumor differentiation, advanced TNM stage, vascular invasion, absen...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.09.001

    authors: Zhang CZ,Cao Y,Fu J,Yun JP,Zhang MF

    更新日期:2016-12-01 00:00:00

  • EMT and inflammation: inseparable actors of cancer progression.

    abstract::Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of inflammatory and immune cells. Tumor-associated chronic inflammation is a hallmark of cancer that fosters progression to a metastatic stage, as has been extensively reviewed lately. Indeed, inflammatory cells persisting in the tu...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12095

    authors: Suarez-Carmona M,Lesage J,Cataldo D,Gilles C

    更新日期:2017-07-01 00:00:00

  • Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

    abstract:PURPOSE:Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). We sought to characterize the transcriptomic features of LCIS and ILC, with a focus on the identification of intrinsic molecular subtypes of LCIS and the changes involved in the progression ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.12.005

    authors: Andrade VP,Morrogh M,Qin LX,Olvera N,Giri D,Muhsen S,Sakr RA,Schizas M,Ng CK,Arroyo CD,Brogi E,Viale A,Morrow M,Reis-Filho JS,King TA

    更新日期:2015-04-01 00:00:00

  • Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

    abstract::Hypoxia is a feature of the microenvironment of many cancers and can trigger epithelial-mesenchymal transition (EMT), a process by which cells acquire a more invasive phenotype with enriched survival. A remodeling of adenosine 5'-triphosphate (ATP)-induced Ca(2+) signaling via purinergic receptors is associated with e...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.09.006

    authors: Azimi I,Beilby H,Davis FM,Marcial DL,Kenny PA,Thompson EW,Roberts-Thomson SJ,Monteith GR

    更新日期:2016-01-01 00:00:00

  • Cell-to-cell communication: microRNAs as hormones.

    abstract::Mammalian cells can release different types of extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies. Accumulating evidence suggests that EVs play a role in cell-to-cell communication within the tumor microenvironment. EVs' components, such as proteins, noncoding RNAs [microRNAs (miRNAs...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12144

    authors: Bayraktar R,Van Roosbroeck K,Calin GA

    更新日期:2017-12-01 00:00:00

  • Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.

    abstract::High throughput gene expression profiling has showed great promise in providing insight into molecular mechanisms. Metastasis-related mRNAs may potentially enrich genes with the ability to predict cancer recurrence, therefore we attempted to build a recurrence-associated gene signature to improve prognostic prediction...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12117

    authors: Tian X,Zhu X,Yan T,Yu C,Shen C,Hu Y,Hong J,Chen H,Fang JY

    更新日期:2017-11-01 00:00:00

  • Exosomal miR-1255b-5p targets human telomerase reverse transcriptase in colorectal cancer cells to suppress epithelial-to-mesenchymal transition.

    abstract::Cancer cells undergo epithelial-to-mesenchymal transition (EMT) in response to hypoxia. Exosomes produced in tumor microenvironments carry microRNAs (miRNAs) that affect proliferation, metastasis, and EMT. Hypoxic regulation of EMT is associated with telomerase content and stability, but the underlying mechanisms rema...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12765

    authors: Zhang X,Bai J,Yin H,Long L,Zheng Z,Wang Q,Chen F,Yu X,Zhou Y

    更新日期:2020-10-01 00:00:00

  • Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.

    abstract::Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton-interfering pharmacophores, in testicular germ cell tumors (T...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12582

    authors: Steinemann G,Dittmer A,Schmidt J,Josuttis D,Fähling M,Biersack B,Beindorff N,Jolante Koziolek E,Schobert R,Brenner W,Müller T,Nitzsche B,Höpfner M

    更新日期:2019-12-01 00:00:00